Safety of Fondaparinux After Low-Molecular-Weight Heparin in Bleeding-Complicated High-Risk Pregnancies: A PSM Cohort Study - PubMed
4 hours ago
- #Anticoagulation
- #Fondaparinux
- #Pregnancy Safety
- Fondaparinux (FPX) may be a safe alternative to low-molecular-weight heparin (LMWH) in high-risk pregnancies when bleeding complications occur.
- The study found comparable rates of miscarriage, live birth, gestational age at delivery, Apgar scores, and neonatal ICU admission between FPX and LMWH groups.
- Postpartum blood loss within 48 hours was significantly lower in the FPX group compared to LMWH, while neonatal birth weight was modestly lower with FPX.
- FPX demonstrated a safety profile similar to LMWH, with no increase in adverse maternal or neonatal outcomes in the matched cohort analysis.
- Further validation through multicenter and prospective studies is needed to confirm these findings and support clinical use of FPX as an alternative.